Placebo Period 2

Preclinical

Placebo Period 2 is one of 4 therapeutic programs targeting OSA - Obstructive Sleep Apnea. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

OSA - Obstructive Sleep ApneaNot yet recruiting

OSA - Obstructive Sleep ApneaPreclinical

Not yet recruiting

Competition

Competitive Landscape

5 competitors in OSA - Obstructive Sleep Apnea

#DrugCompanyPhaseTrials

Dayvigo

Eisai

Phase 2

1 2

Lunesta

Akero Therapeutics

Phase 2

1 3

XW003

HHangzhou Sciwind Biosciences Co., Ltd.

Phase 3

2 4

Placebo Period 2

CChulalongkorn University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

PreclinicalNot yet recruiting

OSA - Obstructive Sleep Apnea

NCT07683442

Clinical

Trials by Indication[1]

OSA - Obstructive Sleep Apnea1 trial

One-Month Dosing of Lemborexant for Treatment of Moderate OSA Patients With Low Arousal Threshold, a Randomized, Double-blind, Crossover, Placebo-Controlled Trial

Not yet recruiting·CChulalongkorn University·Preclinical·NCT07683442·36 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Placebo Period 2. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Placebo Period 2. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Chulalongkorn University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: CChulalongkorn University

Placebo Period 2

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

OSA - Obstructive Sleep Apnea1 trial

References

Drug Info

Quick Facts

Related News